Vera Therapeutics, Inc. $VERA Shares Purchased by UBS Group AG

UBS Group AG boosted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 27.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 207,289 shares of the company’s stock after buying an additional 45,214 shares during the quarter. UBS Group AG’s holdings in Vera Therapeutics were worth $10,497,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Deerfield Management Company L.P. increased its stake in Vera Therapeutics by 8.8% in the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after purchasing an additional 293,040 shares during the last quarter. Vanguard Group Inc. increased its stake in Vera Therapeutics by 11.9% during the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after acquiring an additional 379,748 shares during the last quarter. Vestal Point Capital LP increased its stake in Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after acquiring an additional 600,000 shares during the last quarter. Integral Health Asset Management LLC increased its stake in Vera Therapeutics by 47.8% during the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock worth $49,402,000 after acquiring an additional 550,000 shares during the last quarter. Finally, Schroder Investment Management Group increased its stake in Vera Therapeutics by 82.4% during the third quarter. Schroder Investment Management Group now owns 679,992 shares of the company’s stock worth $19,652,000 after acquiring an additional 307,243 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Price Performance

VERA stock opened at $37.32 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a 1 year low of $18.76 and a 1 year high of $56.05. The firm has a market cap of $2.68 billion, a P/E ratio of -6.74 and a beta of 0.96. The stock has a 50-day simple moving average of $39.59 and a 200-day simple moving average of $40.61.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter last year, the business posted ($0.81) earnings per share. On average, equities analysts predict that Vera Therapeutics, Inc. will post -5.9 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Laurence Matthew Skelton sold 1,582 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $66,412.36. Following the completion of the sale, the insider owned 64,218 shares in the company, valued at approximately $2,695,871.64. This trade represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $36.74, for a total value of $679,690.00. Following the completion of the sale, the chief executive officer owned 216,744 shares of the company’s stock, valued at approximately $7,963,174.56. This trade represents a 7.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 74,941 shares of company stock valued at $3,096,592. Company insiders own 15.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on VERA. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Evercore set a $91.00 price target on Vera Therapeutics in a research note on Friday. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a research note on Wednesday, March 11th. Finally, HC Wainwright upped their price target on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $79.00.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.